MUMBAI, India — Glenmark Pharmaceuticals Inc. USA has received final approval from the Food and Drug Administration for desmopressin acetate tablets in strengths of 0.1 mg and 0.2 mg.

The company said Friday that the product, a generic equivalent of DDAVP (0.1 mg and 0.2 mg) from Ferring Pharmaceuticals Inc., has begun shipping.

Desmopressin is a synthetic version of vasopressin, the hormone that reduces urine production. It is most often prescribed for treatment of diabetes insipidus, bedwetting or nocturia (waking up at night to urinate).

The the DDAVP market had U.S. sales of approximately $72.1 million through the 12 months ended in March, according to IMS Health data reported by Glenmark.